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Background. The objective of this report was to estimate long-term outcome and prognostic 
factors in children and adolescents with osteosarcoma. A large group of osteosarcoma patients 
were analyzed at our national oncology center. 
Procedure. To evaluate the efficacy of surgery and multiagent chemotherapy for treating 
osteosarcoma, we reviewed 122 cases (65 male, 57 female, mean age 13.8 ± 3.6 years) treated at 
the Second Department of Pediatrics in Budapest between 1988 and 2006. Demographic 
parameters, tumor-related and treatment-related variables, response, overall survival (OS) and 
event-free survival (EFS) were analyzed.  
Results. The 5-year OS was 68% and 5-year EFS was 62%. OS of patients without metastasis 
was 79%, while OS with early metastasis was 17%. Survival of patients with amputation (n = 30) 
was not significantly different from patients with limb-salvage surgery (n = 82), but all patients 
without radical surgery died. Gender and histological classification had no prognostic 
significance. Patients with localized tumors in extremities had increased survival compared to 
patients with axial skeleton tumors (p = 0.013). Poor histological response to neoadjuvant 
chemotherapy (rate of survivor tumor cells >10%) was associated with decreased survival (p = 
0.018). Patients under 14 years had better EFS than patients over 14 years (p = 0.008). 
Conclusions.  Our results demonstrate that younger patients with localized osteosarcoma of the 
extremities who receive limb-salvage surgery and chemotherapy have an excellent survival. 
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Osteosarcoma is the most common primary malignant bone tumor in children and adolescents, 
yet its absolute incidence among malignant tumors is low. The incidence of newly diagnosed 
cases peaks in the second decade of life (1). As osteosarcoma may produce various kinds of extra 
cellular matrix and have different degrees of differentiation, huge variability exists in histological 
patterns. Conventional osteosarcoma can be divided into osteoblastic, chondroblastic, and 
fibroblastic subtypes depending on the predominant type of extracellular matrix (2). The etiology 
of osteosarcoma in young patients is unexplained. Osteosarcoma could potentially derive from 
any cell on the differentiation pathway between a mesenchymal stem cell and a mature osteoblast 
(3).  
The goal of bone sarcoma therapy is curing the patient of both the primary tumor and all (micro-) 
metastatic deposits while maintaining maximal extremity function and minimalizing treatment-
specific late side effects. Bone sarcoma therapy involves close multidisciplinary coordination of 
oncologists, orthopedic surgeons, musculoskeletal pathologists and radiologists. It usually 
consists of induction neoadjuvant chemotherapy followed by local therapy of the primary tumor 
and any primary metastases, and adjuvant chemotherapy. Local treatment for osteosarcoma 
should be surgery whenever possible (4). After the introduction of adjuvant chemotherapy in the 
1970s, survival has increased from 10–20% to 50–80%. Doxorubicin, cisplatin, ifosfamide and 
methotrexate are currently the most effective agents for patients with osteosarcoma (5). Advances 
in imaging, new materials, and prostheses have assisted surgeons in making more accurate 
preoperative plans and giving them a broader range of operative alternatives.  
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Chemotherapy response; presence of metastatic disease; tumor size and site, with axial locations 
worse then location of extremities, are reported to be independent prognostic factors of 
osteosarcoma (6). At the time of diagnosis, 20% of patients already present with distant 
metastases, with lung the most frequent metastatic site (5). The prognosis of patients with 
recurrent disease or metastases at diagnosis is poor. Resection of pulmonary metastases is a 
standard treatment for lung relapse of a tumor. Survival of patients who have surgery is 36% after 
5 years, and 26% after 10 years (7). Unresectable tumors increase the risk of local recurrence and 
result in poor prognosis. (4) 
In this retrospective analysis, we collected data on children with osteosarcoma diagnosed 
between 1988 and 2006 in the Second Department of Pediatrics in Budapest. This disease is rare, 
so the aim of our study was to examine prognostic significance of factors based on a large cohort 
of patients homogeneous for ethnic group and treatment. 
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 Between 1988 and 2006, 172 pediatric patients (data collected by the National Pediatric 
Tumor Registry of Hungary) were diagnosed with osteosarcoma in Hungary. Osteosarcoma 
patients could be treated at three pediatric oncology centers in the country. The largest is the 
Second Department of Pediatrics in Budapest, where 70% of the subjects were treated (122 
patients). We retrospectively collected clinical data on these patients (65 males and 57 females; 
mean age at diagnosis: 13.8 ± 3.6 standard deviation [SD], range: 5.5-17.6 years). 
The patients were treated according to the Cooperative Osteosarcoma Study Group 
(COSS) 86 (8) and later COSS 96 protocols (9) including neoadjuvant and adjuvant 
chemotherapy, and radical surgery (Figure 1). The differences between the two protocols were 
that the COSS 96 protocol had a shorter low-risk arm and introduced a new branch with 
increased methotrexate. In Hungary, we used only the standard arms. We did not randomize the 
study, so the two protocols had no relevant differences in drugs, dosage, or schedule. 
Neoadjuvant chemotherapy included one course of doxorubicin (90 mg/m2), two courses of high-
dose methotrexate (12 g/m2), and two courses of ifosfamide (2x3g/m2) plus cisplatin (120 
mg/m2). The surgical decision about surgery type was based on tumor volume at the time of 
diagnosis, and on X-ray and Magnetic Resonance imaging (MRI) examinations before and after 
neoadjuvant chemotherapy. In addition, orthopedic surgeons estimated whether the resection 
margin was large enough, and if the salvaged limb would be functional. After radical operation of 
the tumor (amputation or limb-sparing surgery) patients were classified into risk groups and an 
additional 6-8 months of chemotherapy was administered. Classification into a risk group was 
based on the initial volume of the tumor and chemotherapy response of the tumor cells (Table I-
II). Histological response to chemotherapy was characterized by the degree of necrosis detected 
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by histological examination of multiple tumor sections after neoadjuvant chemotherapy and 
surgery. According to the COSS protocols, patients were defined as good responders if less than 
10% of the tumor cells were alive after neoadjuvant therapy, or poor responders if the extent of 
necrosis was less than 90%. For adjuvant chemotherapy, the new drugs carboplatin (4 x 150 
mg/m2) and etoposid (4 x 150 mg/m2) were introduced in the high-risk arm. The other arms of 
the protocol used the same chemotherapeutic agents as for neoadjuvant therapy. 
We examined 5-year overall survival (OS) and 5-year event-free survival (EFS). A patient 
is considered to be cured after a 5-year event-free period. Patients were divided into subgroups by 
metastasis (none; early, defined as at diagnosis; or late); type of surgery (biopsy, amputation, 
limb salvage), chemotherapy protocol (COSS 86 or 96), tumor site (axial skeleton, upper or lower 
extremity), gender (male or female), histological subtypes (osteoblastic, chondroblastic, 
fibroblastic, or other), histological response to pre-operative chemotherapy (poor or good 
response); and age at diagnosis (over or under 14 years).  
We used StatSoft’s STATISTICA v8.0 program for statistical analyses. Survival data 
were analyzed by the Kaplan-Meier method. For finding relationships between survival and these 
different factors, actuarial analyses with log-rank tests were used. 
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For the entire cohort, the 5-year OS was 68% and the EFS 62% (Figure 2). Results are in 
Table III. Of the 122 children, 37 had metastasis, local relapse or both (Figure 3). Of 37 cases, 15 
had early metastasis at the time of diagnosis, with an OS of 16.6%. In 11 cases, metastases were 
in the lungs, in 3 cases, in the bone, and in 1 case in the kidney. Only three patients with early 
metastases survived. In our patient population, 13 children had late metastases with an OS of 
41.6%. All had pulmonary metastases, and four also had metastases in the regional lymphatic 
glands. Eight had both local relapse and metastasis. Late pulmonary metastases were treated with 
thoracotomy and postoperative chemotherapy in 13 children, with 5 surviving. The OS of 
nonmetastatic patients was 79% (Figure 4A). Dependence of OS on the time of metastasis 
appearance was significant (p = 0.00002). 
Of 23 patients with local relapses, 18 died (Figure 3). All patients with local recurrence 
relapsed despite primary tumor surgery. Limb salvage surgery was performed on 16 patients 
before relapse. Six patients had early metastases and local relapse together, and five of these died. 
Eight patients had late metastases and local relapse together, and six died. Isolated local 
recurrence was found in 9 patients, with 2 long-term. The median time to develop local 
recurrence was 16 months from the date of diagnosis (range: 0.4–118.3 months). 
 We also analyzed by type of surgery (Figure 4B). All patients who did not undergo radical 
surgery died. Although 30 patients underwent an amputation, in the last 10 years more than 85% 
of patients have undergone limb-salvage surgery, with most of them receiving tumor 
endoprothesis. EFS was 57% for amputation cases and 68% for limb-saving surgery cases. The 
survival rate of patients undergoing amputation was somewhat lower than those receiving limb-
salvage surgeries, because orthopedists chose amputation for patients with a larger tumor volume 
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or for whom neoadjuvant chemotherapy had been ineffective. These patients have a poor 
prognosis. No signficant difference in survival was observed between the two types of surgical 
procedure (p = 0.3), although patients with biopsy only had significantly worse outcomes 
(p=0.00005).  
 There was no difference in survival between patients diagnosed before or after 1995 (p = 
0.6) (Figure 5A). We chose 1995 as the cut-off because COSS 86 was used from 1988-1995, and 
COSS 96 was used from 1996-2006. In the group treated according to COSS 86, EFS was 57%; it 
was 64% for the group treated with COSS 96. 
 We analyzed the relationship between EFS and tumor site and found no significant 
difference in survival if the primary tumor was in the upper or lower extremity (p = 0.7). In both 
cases, EFS was around 60% (upper extremity 56.3% vs. lower extremity 65%), while tumors of 
the axial skeleton showed a much worse survival rate of 22.2% (p = 0.013) (Figure 5D). 
 Boys and girls showed the same survival rates (p = 0.5) (Figure 5B), with an EFS of 65% 
for girls and 57% for boys. We observed no differences in survival rates between osteosarcoma 
histological subgroups (p=0.9) (Figure 5C). A significant difference was detected in survival rate 
between poor and good responders (p = 0.018). The EFS was 77% for good responders and 50% 
for poor responders (Figure 4C). Significantly better results were achieved with patients younger 
than 14 years than with patients over 14 years (p = 0.008). While the EFS of the patients over 14 
years was only 48.4%, the EFS of patients under 14 years was 74.1% (Figure 4D). We were 
unable to collect tumor volume data because 60% of these data were missing or incorrect because 
poor documentation.  
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Osteosarcoma in childhood was curable by the COSS 86 and COSS 96 protocols, with 
68% of our patients achieving long-term survivor status. Previous COSS protocols had poorer 
survival results. For example, the COSS 77 protocol had an OS of only 47% (10). 
Our results correspond with the international data. The combined use of surgery and multidrug 
chemotherapy results in 5-year EFS rates of approximately 50–70% in patients with localized 
extremity osteosarcoma (4). Ferrari et al. (11) found that patients aged less than 40 years with 
nonmetastatic osteosarcoma of the extremity had an expected 5-year survival rate of 70% with a 
chemotherapy regimen based on methotrexate, cisplatin, doxorubicin, and ifosfamide. Further 
improvement cannot be achieved by dose intensification of treatment, and new strategies are 
required. Prolonged follow-up is mandatory due to the risk of late side effects, second tumors and 
late relapse of osteosarcoma (11). Jaffe established that disease-free survival increased from 
<20% to 55-75% after the introduction of effective chemotherapy. Furthermore, limb salvage 
expanded to 80% of patients (12). An international collaboration between Western Europe, 
Turkey, Croatia, and the USA examined prognostic factors and outcomes for osteosarcoma and 
found that the 5-year mortality risk of osteosarcoma was 48%. Most of the 2680 patients (78%) 
had combined surgery and chemotherapy, 14% had surgery alone, 3% had chemotherapy alone, 
and 5% had other combinations or treatments (13). We found that the most important prognostic 
factors of osteosarcoma are radical resecability of the tumor, extent of disease at diagnosis, initial 
tumor volume, and initial response of tumor cells to neoadjuvant chemotherapy. 
Reconstructive techniques have improved substantially over the past decades, particularly for 
young patients who have not yet reached skeletal maturity. Studies of osteosarcoma have 
Page 9 of 25
John Wiley & Sons
Pediatric Blood & Cancer
For Peer Review
 10 
consistently shown an increased risk of local recurrence in patients undergoing limb-salvage 
surgery, but no increase in mortality. Local recurrence in osteosarcoma is directly associated with 
the margins of excision and with the responsiveness of the primary tumor to chemotherapy; in 
patients with a close margin of excision and less than 90% necrosis of the tumor after 
neoadjuvant chemotherapy, local recurrence can be as high as 30% (14). Rozeman et al. found 
the incidence of local relapses (5-10%) was higher after limb-salvage surgery than after 
amputation (0.5-2%) (5). In our data, the rate of local relapses after limb-salvage surgery was 
slightly higher (14%). Approximately 90-95% of local recurrences appear after limb-salvage 
surgery, especially when surgical incision is not sufficiently radical. However, amputation to 
achieve cure has not led to improved survival compared with limb-salvage techniques. The 
challenge for the surgeon is to reconstruct the limb to allow the child to grow as normally as 
possible (15). 
At least 30–40% of patients with osteosarcoma develop metastases, of which over 80% include 
the lungs and approximately 15% distant bones. Our results show that the number of lesions at 
diagnosis has prognostic significance in osteosarcoma. Either presence of metastases or local 
recurrence triples the mortality risk. The 5-year risk of metastasis was 45% in Pakkos et al. (13). 
By multivariate analysis, the presence of metastases increased the risk for a new metastasis five-
fold, but no other clinical or demographic characteristics were independently associated with 
metastasis risk (13). In patients with osteosarcoma of the extremity with lung metastases, a 
combination of aggressive chemotherapy with simultaneous resection of primary and metastatic 
tumors can be a therapeutic approach (16). In this study, the mean survival rate of patients with 
lung metastasis is 10-30%. The length of the relapse-free interval is also an important prognostic 
factor. In cases of early metastasis, almost all patients died while the OS rate of late metastatic 
patients was quite good in our study (42%). 
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Initial tumor size is an important prognostic factor in osteosarcoma. When involvement of 
neighboring tissues is high, radical surgery is more difficult, and the chance of distant metastasis 
increases, resulting in a lower survival rate in cases of larger tumors. Bacci et al. found that tumor 
volume greater than 200 mL was significantly correlated with increased risk of recurrence (17). 
In a review of St. Jude Children's Research Hospital studies, metastatic disease was associated 
with tumor diameters over 8 cm (p = 0.002) (18). For technical reasons, we were not able to 
analyze the effect of initial tumor volume on prognosis. 
Histological tumor response to neoadjuvant chemotherapy after surgery correlates with risk of 
recurrence. Good responders have less than 10% viable tumor cells. At our center, their 5-year 
OS was 84% and their 5-year EFS was 77.3%, while OS for poor responders was only 55.3%, 
and EFS was only 50%. Several international data support the importance of tumor response for 
survival. Pakkos et al. (13) observed that tumor necrosis was a strong predictor for all major 
clinical outcomes (13). Another trial of 497 patients showed that intensification of chemotherapy 
improves histological response without concomitant improvement in progression-free survival or 
OS (19). 
Our results showed that tumors of the axial skeleton had a much worse prognosis than the tumors 
of the extremities because of the difficulties of radical surgery in this region. Without radical 
operation, the prognosis for osteosarcoma is very poor. Surgery plays a key role in long-term 
survival, as only 10% of patients with osteosarcoma are cured by chemotherapy alone (20). 
From the literature, the importance of age at diagnosis as a prognostic factor in 
osteosarcoma patients is unclear. A better prognosis for younger patients was reported by Bielack 
et al., who found that patient age at diagnosis (actuarial 10-year survival of patients older than 40 
years = 41.6%; patients younger than 40 years EFS = 60.2%; p = 0.012) had significant influence 
on outcome (21). A study by Harting et al. (22) consisted of 438 patients of all ages diagnosed 
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with osteosarcoma between 1980 and 2000 who underwent the majority of their treatment at MD 
Anderson Cancer Center. By univariate analyses, an age of 40 or over was found to be a poor 
prognostic factor, however age was not identified as a significant prognostic variable by 
multivariate analysis (22). A retrospective analysis of Szendroi et al. showed that age over 30 
years had indirect negative influence on the final outcome through higher intolerability to drugs 
and lower cooperation from the patient (23). Bacci et al. found that patients 14 years old or 
younger had an independently worse prognosis than older patients (17). In contrast, in our study, 
significantly better results were achieved in patients younger than 14 years than in patients over 
14 years (p = 0.008). Pakos et al. found that, for 2680 patients with osteosarcoma, survival was 
worse with older age (7% relative risk increase per decade) by multivariate analyses (13). 
Patients with suspected or confirmed osteosarcoma should be evaluated and treated at a 
comprehensive cancer center within a multidisciplinary sarcoma program that includes pediatric, 
medical and radiation oncologists; orthopedic and surgical oncologists; musculoskeletal 
pathologists; and radiologists. Successful treatment involves adequate diagnosis, preoperative and 
adjuvant multiagent chemotherapy, and aggressive surgery with an emphasis toward limb 
preservation. Patients treated for osteosarcoma should be followed closely both for relapse of 
disease and for development of late effects from chemotherapy (24). 
Osteosarcoma is a radioresistant lesion (24). Radiotherapy is used for palliative therapy in 
patients with radically inoperable tumors. Radiation therapy may represent an alternative to 
definite surgery in selected patients, in particular those with good response to chemotherapy, for 
whom surgery is either not feasible or refused (25). We used radiotherapy for palliative treatment 
in only two cases. 
Based on this Hungarian population, we conclude that 68% of patients are curable through 
intensive chemotherapy and surgery. Limb-salvage surgery is not associated with a significantly 
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increased risk of adverse events, but gives much better quality of life. Patients with metastatic 
disease or local relapse have a very poor prognosis. Nonmetastatic cases, cases of tumors of the 
extremities, and patients under 14 years have a survival of 80%. To further improve survival, a 
continued emphasis should be placed on preclinical basic science and translational research 
aimed at furthering our understanding of osteosarcoma with the intention of providing patients 
with new, molecularly targeted therapies. 
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Table I.  Definition of the risk groups 
Risk group Definition 
Low risk group tumor volume ≤70 ml without reference to histological regression 
or tumor volume: 71-150 ml and the histological regression I/II 
Standard risk group tumor volume: 71-150 and the histological regression III-IV 
or tumor volume ≥150ml and the histological regression I-IV 
High risk group tumor volume ≥150 ml and the histological regression V/VI 
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Table II. Grade of histological regression of osteosarcoma after neoadjuvant chemotherapy 
 
Grade Definition 
I. no survivor tumor cells 
II. sporadically one-one tumor cell or one survivor tumor cell island which is smaller than 0.20 inch 
(0.5 cm) 
III. rate of the survivor tumor cells less than 10% 
IV. rate of the survivor tumor cells 10-50% 
V. rate of the survivor tumor cells more than 50% 
VI. ineffective chemotherapy 
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Table III. Overview of prognostic factors analyzed in our study 
______________________________________________________________________________________ 
 
Subgroups  Overall  p value  Event-free p value 
    survival (%) (OS)  survival (%)  (EFS) 
______________________________________________________________________________________ 
 
Whole cohort   68.0     62     
    
Metastasis 
No metastasis  79 
Early metastasis  16.6  0.00002 
Late metastasis  41.6 
 
Type of surgery 
Biopsy   0    0 
Amputation   63.3  < 0.00005 56.6  0.00005 
Limb salvage   76.9    68.3 
 
Chemotherapy protocol 
COSS 86 (1988-1995) 62  0.30883  57  0.62776 
COSS 96 (1996-2006) 73.5    64 
 
Localization 
Axial skeleton  33.3    22.2 
Upper extremity  68.7  0.01626  56.3  0.0133 
Lower extremity  71.1    65 
 
Gender 
Boys   66.2  0.68473  57  0.48097 
Girls   70.2    65 
 
histological subtypes 
Osteoblastic    67.7    64.5 
Chondroblastic   62.5  0.96227  56.3  0.87902 
Fibroblastic   73.3    60 
Else   69    58.6 
 
Response to pre-operative chemotherapy 
Poor response   55.3  0.00974  50  0.0182 
Good response  84    77.3 
 
age at diagnosis 
younger than 14 years 77.6  0.04383  74.1  0.0085 
older than 14 years  59.4    48.4 
______________________________________________________________________________________ 
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Figure 1. COSS 96 protocol. 
A, doxorubicin 90 mg/m2; C, carboplatin 4 x150 mg/m2; E, etoposid 4 x150 mg/m2; I, ifosfamide 
2 x 3g/m2; M, high-dose methotrexate 12 g/m2; OP: date of operation; P, cisplatin 120 mg/m2; R: 
randomization.  
359x180mm (600 x 600 DPI)  
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Figure 2. Survival of all patients with osteosarcoma. 
OS =68% (blue line), EFS = 62% (red line).  
151x105mm (600 x 600 DPI)  
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Figure 3. Flow diagram of patients with osteosarcoma treated at the Second Department of Pediatric 
in Budapest between 1988-2006.  
160x120mm (600 x 600 DPI)  
 
 
Page 23 of 25
John Wiley & Sons





Figure 4. Survival of patients by factors with significant prognostic value. 
(A) OS of patients by metastasis, p = 0.00002. No met (blue line) OS = 78.95%, early 
met (red line) OS = 16.66%, late met (green line) OS = 41.66%; (B) EFS of patients according to 
the type of surgery, p = 0.00005. Biopsy (blue line) EFS = 0.00%, amputation (red line) EFS = 
56.66%, limb-salvage surgery (green line) EFS = 68.29%; (C) EFS by response to pre-operative 
chemotherapy, p = 0.0182. Poor response (red line) EFS = 50.00%, good response (blue line) EFS 
= 77.27; (D) EFS by age at diagnosis, p = 0.0085, younger than 14 years (red line) EFS = 74.14%, 
older than 14 years (blue line) EFS = 48.4%; Abbreviations: EFS, event-free survival; met, 
metastasis; OS, overall survival.  
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Figure 5. Survival of patients according to factors without significant prognostic value. 
(A) EFS by date of diagnosis p = 0.62776, Dg between 1988-1995 (blue line) EFS = 56.90%, Dg 
between 1996-2006 (red line) EFS = 64.06%; (B) EFS by gender p = 0.48097. Girls (blue line) EFS 
= 64.91%, boys (red line) EFS = 56.92%; (C) EFS by histological subtype, p = 0.87902, 
osteoblastic (blue line) EFS = 64.56%, chondroblastic (red line) EFS = 56.25%, fibroblastic (green 
line) EFS = 60.00%, other (purple line) EFS = 58.62%; (D) EFS by localization, p = 0.7, upper 
extremity (red line) EFS = 56.25%, lower extremity (green line) EFS = 64.94%, axial skeleton (blue 
line) EFS = 22.22% (p = 0.0133); abbreviations: Dg, diagnosis; EFS, event-free survival.  
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